Update: Cellceutix Calls Out To President Obama About Brilacidin
- On September 19, 2014, CTIX issued a bold press release about a new Executive Order relating to antibiotic resistance.
- The company expects top line data from the Brilacidin Phase 2b trial to be positive. The entire defensin-mimetic portfolio is expected to be supported by the new Presidential Order.
- President Obama’s signing of the Executive Order on September 18, 2014 to combat the threat from bacteria resistant to current antibiotic treatment was unexpected. This changes the antibiotic space.